Ignite Creation Date:
2024-05-05 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00158210
Status:
COMPLETED
Last Update Posted:
2017-01-12
First Post:
2005-09-08
Brief Title:
Rivastigmine For Methamphetamine Dependent Individuals
Sponsor:
National Institute on Drug Abuse NIDA
Organization:
National Institute on Drug Abuse NIDA
Study Overview
Official Title:
Double-Blind Randomized Placebo Controlled Trial of Rivastigmine Excelon as a Potential Medication for Methamphetamine Abuse
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Methamphetamine abuse has been steadily increasing over the past decade Rivastigmine is a medication that may be helpful in treating methamphetamine dependence The purpose of this study is to evaluate the effectiveness of rivastigmine in treating methamphetamine dependent individuals
Detailed Description:
Methamphetamine is a powerful stimulant that affects the central nervous system Chronic methamphetamine use often leads to psychotic behavior Rivastigmine is an acetylcholinesterase inhibitor that is currently approved to treat Alzheimers-related dementia The purpose of this study is to assess the efficacy of rivastigmine in treating methamphetamine dependent individuals
Participants will be randomly assigned to either one of two dose levels of rivastigmine or placebo for 12 weeks Participants will be assessed for cardiovascular subjective and reinforcing effects that are produced by methamphetamine All participants will partake in contingency management sessions through Week 4
Participants will be randomly assigned to either one of two dose levels of rivastigmine or placebo for 12 weeks Participants will be assessed for cardiovascular subjective and reinforcing effects that are produced by methamphetamine All participants will partake in contingency management sessions through Week 4
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| DPMCDA | US NIH GrantContract | None | httpsreporternihgovquickSearchP50DA018185 |
| P50DA018185 | NIH | None | None |